Aprea AB has raised €46 million in a Series B equity financing co-led by Versant Ventures and 5AM Ventures. The privately-held Swedish company is developing a small molecule drug that reactivates a tumour suppressor protein known as p53. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
